India, April 15 -- Hoth Therapeutics, Inc.(HOTH) Tuesday reported positive interim data from its Phase 2a study dubbed CLEER-001, evaluating HT-001 for the treatment of pruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors.
EGFR inhibitors, widely used in oncology, commonly cause skin-related adverse effects, including intense itching.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
In the CLEER-001 study, patients experienced a 50 percent reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Rapid symptom relief was also observed, with mean scores improving to 1.0 by Day 7. Some patients achieved complete resoluti...